Authors
Latest:
Thomas Povsic, MD, PhD, on Ongoing Research With XC001 Angina Gene TherapyThe interventional cardiologist and professor, Duke University School of Medicine, discussed other populations that may benefit from XC001 and the challenges and opportunities with a surgical delivery of treatment.
Latest:
1-Year Data on Omidubicel Shows Sustained Benefits, Reduced Infection RatesThere was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.
Latest:
The Growing Popularity of Gene Therapy for Retinal DiseasesFoundation Fighting Blindness is helping to support the development of gene therapies for retinal diseases.
Latest:
Advantages of CG0070 Over Standard Care for Non-Muscle Invasive Bladder CancerThe chief executive officer of CG Oncology discussed the role of CG0070 in patients who are unresponsive and responsive to Bacillus Calmette-Guerin immunotherapy.
Latest:
Re-Dosing With Gene Therapies in Rare DiseasesTakashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.
Latest:
The Importance of Collaboration in Developing Next Generation Cell TherapiesDolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies.
Latest:
Devon J. Shedlock, PhD, on Shifting from Autologous to Allogeneic TherapiesThe chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.
Latest:
Mesenchymal Stem Cells and Other Upcoming Treatments for Progressive MS: Jeffrey Cohen, MDThe director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed upcoming new therapies for relapsing MS.
Latest:
Angela Genge, MD, FRCPC, eMBA, on Targeting STMN2 to Rescue Neurons in ALSThe chief medical officer of QurAlis discussed the antisense oligonucleotide therapy QRL-201.
Latest:
Next Steps for Car T-Cell Therapy in Multiple Myeloma: Faith E. Davies, MDThe director of the Clinical Myeloma Program at NYU Langone Health’s Perlmutter Cancer Center discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.
Latest:
Caspian Oliai, MD, MS, on Making Allo-Transplant Safer for Older PatientsThe medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center discussed results from a phase 1b trial for allo-HCT alternative Orca-T that he presented at Tandem’s 2024 conference.
Latest:
Clinical Implications of CAR T-Cell Therapy in R/R Myeloma: Frits van Rhee, MD, PhDThe professor and director of the Myeloma Center at the University of Arkansas for Medical Sciences discussed the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.
Latest:
Gene Therapy: The Future of Rare Disease TreatmentExperts shared opinions about the future of gene therapy in sickle cell and other rare diseases.
Latest:
Stem Cell vs Gene Therapy Processes in Sickle Cell DiseaseA discussion of the course of gene therapy compared with stem cell therapy.
Latest:
Stem Cell vs Gene Therapy Processes in Sickle Cell DiseaseA discussion of the course of gene therapy compared with stem cell therapy.
Latest:
Stem Cell vs Gene Therapy Processes in Sickle Cell DiseaseA discussion of the course of gene therapy compared with stem cell therapy.
Latest:
Carsten Bönnemann, MD, on Identifying At-Risk Genotypes for DMD Gene TherapyThe senior investigator from NINDS discussed findings investigating serious AEs across different trials.
Latest:
Ongoing Gene Therapy Trials in Stargardt Disease : Prof. Carel HoyngThe professor of ophthalmology from Radboud University, The Netherlands, discussed ongoing gene therapy trials in Stargardt disease.
Latest:
N. Nora Bennani, MD, on VSV Therapy and Other Novel Therapies for Lymphoma, MyelomaThe assistant professor at Mayo Clinic School of Medicine discussed plans for further research and a phase 2/3 study.
Latest:
B-VEC Shows Quality of Life Improvements in Dystrophic Epidermolysis BullosaKrystal Biotech's investigational topical gene therapy has shown promise in DEB. It is designed to deliver COL7A1 and restore C7 protein in patients with the rare disorder.
Latest:
Giedre Krenciute, PhD, on Revitalizing T-cells in CAR T-cell TherapyThe assistant member of the bone marrow transplantation and cellular therapy department at St. Jude Children’s Hospital discussed preclinical research presented at ASH 2022.
Latest:
Pursuing Slow but Steady Gene Therapy DevelopmentMichael Parini, chief executive officer and director, Freeline Therapeutics, discussed the company’s pipeline and mission.
Latest:
Aimee C. Talleur, MD, on the Challenge of Evaluating Late Effects from CAR-T in Pediatric PatientsThe physician from St. Jude Children’s Research Hospital discussed the importance of involvement from patients and families while researching the long-term impact of CAR-T.
Latest:
Rigo Garcia, MPH, on Improving DE&I in Rare Disease Health CareThe executive director of Hemophilia Foundation Southern California discussed issues with minorities accessing care for rare diseases and strategies to mitigate them.
Latest:
Utility of CART22-65s and huCART19 in R/R ALL: Noelle V. Frey, MD, MSCEThe associate professor from Perelman School of Medicine, University of Pennsylvania, discussed co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia.
Latest:
CAR T-Cell Therapy for Mantle Cell Lymphoma: Tycel Jovelle Phillips, MDThe clinical associate professor from the Rogel Cancer Center at Michigan Medicine discussed the future of CAR T-cell therapy in mantle cell lymphoma patients.
Latest:
Sukumar Nagendran, MD, on the Potential of TSHA-102 in Pediatric Patients With Rett SyndromeThe president and head of R&D at Taysha Gene Therapies discussed his expectation that younger patients my see even better results with the company’s gene therapy than the adult patients treated so far.
Latest:
Amer Beitinjaneh, MD, MSc, MPH, FACP, on Treating EBV+ PTLD With Tab-celThe associate professor of medicine at Sylvester Comprehensive Cancer Center discussed updated data from the phase 3 ALLELE study.
Latest:
Richard James, PhD, on the Potential of Engineered Plasma Cells in CancerThe associate professor at the University of Washington, and principal investigator at Seattle Children's Research Institute discussed results from a leukemia mouse model.
Latest:
Mitchell Horwitz, MD, on Cost-Effectiveness of Omidubicel for Allo-HCTThe professor of medicine at Duke Cancer Institute discussed uptake and research with the cord blood therapy since its approval.
